According to the report published by Allied Market Research, the global Psoriasis Therapeutics Market was estimated at $22.9 billion in 2021 and is expected to hit $55.8 billion by 2031, registering a CAGR of 9.3% from 2022 to 2031. The report provides a detailed analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive landscape, and evolving market trends. The market study is a helpful source of information for the frontrunners, new entrants, investors, and shareholders in crafting strategies for the future and heightening their position in the market.
Download Free Sample Report : https://www.alliedmarketresearch.com/request-sample/3747
- The outbreak of the pandemic gave way to postponement of non-emergency medical treatments, which impacted the global psoriasis therapeutics market negatively, especially during the initial period.
- However, later on, scientists found no evidence that medical interventions to treat psoriasis and psoriatic arthritis should be interrupted or altered to minimize COVID-19 risks, which in turn helped the market recoup soon.
The global psoriasis therapeutics market is analyzed across drug class, type, route of administration, and region. The report takes in an exhaustive analysis of the segments and their sub-segments with the help of tabular and graphical representation. Investors and market players can benefit from the breakdown and devise stratagems based on the highest revenue-generating and fastest-growing segments stated in the report.
Based on drug class, the interleukin inhibitors segment held nearly two-fifths of the total market revenue in 2021, and is expected to dominate by 2031. The same segment would also manifest the fastest CAGR of 10.0% throughout the forecast period.
Based on type, the plaque psoriasis segment held nearly three-fifths of the total market revenue in 2021, and is expected to dominate by 2031. The same segment would also manifest the fastest CAGR of 9.4% throughout the forecast period.
Based on route of administration, the parenteral segment garnered nearly two-fifths of the total market revenue in 2021, and is expected to dominate by 2031. The same segment would also project the fastest CAGR of 10.3% throughout the forecast period.
Based on region, the global psoriasis therapeutics market across North America generated more than two-fifths of the total market revenue in 2021, and is anticipated to retain the lion’s share by 2031. The Asia-Pacific region, however, would showcase the fastest CAGR of 12.0% throughout the forecast period. The other provinces analyzed through the report include Europe and LAMEA.
The key market players analyzed in the global psoriasis therapeutics market report include Bausch Health Companies Inc., Abbvie Inc., Johnson and Johnson, LEO Pharma, Amgen Inc., Novan Inc. (EPI Health LLC), Novartis AG, Pfizer Inc., Eli Lilly and Company, and Viatris Inc. (Mylan NV). These market players have embraced several strategies including partnership, expansion, collaboration, joint ventures, and others to highlight their prowess in the industry. The report is helpful in formulating the business performance, product portfolio, operating segments, and developments by the top players.
Key Findings of the Study
• On the basis of drug class, the interleukin inhibitors segment dominated the psoriasis therapeutics industry in 2021, and is expected to continue this trend during the forecast period.
• On the basis of type, the plaque psoriasis segment dominated the market in 2021, and is expected to continue this trend during the forecast period.
• On the basis of route of administration, the parenteral segment dominated the market in 2021, and is expected to continue this trend during the forecast period.
•Region-wise, North America garnered the largest revenue share in 2021. However, Asia-Pacific is anticipated to grow at the highest CAGR 12.0% during the forecast period.
𝐎𝐭𝐡𝐞𝐫 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬:
Medical Tourism Market–
Diabetes Therapeutics Market —https://www.alliedmarketresearch.com/diabetes-therapeutics-market
𝐀𝐕𝐄𝐍𝐔𝐄- 𝐀 𝐒𝐮𝐛𝐬𝐜𝐫𝐢𝐩𝐭𝐢𝐨𝐧-𝐁𝐚𝐬𝐞𝐝 𝐋𝐢𝐛𝐫𝐚𝐫𝐲 (𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐨𝐧-𝐝𝐞𝐦𝐚𝐧𝐝, 𝐬𝐮𝐛𝐬𝐜𝐫𝐢𝐩𝐭𝐢𝐨𝐧-𝐛𝐚𝐬𝐞𝐝 𝐩𝐫𝐢𝐜𝐢𝐧𝐠 𝐦𝐨𝐝𝐞𝐥) 𝐎𝐟𝐟𝐞𝐫𝐞𝐝 𝐛𝐲 𝐀𝐥𝐥𝐢𝐞𝐝 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡:
AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.
𝐆𝐞𝐭 𝐚𝐧 𝐚𝐜𝐜𝐞𝐬𝐬 𝐭𝐨 𝐭𝐡𝐞 𝐥𝐢𝐛𝐫𝐚𝐫𝐲 𝐨𝐟 𝐫𝐞𝐩𝐨𝐫𝐭𝐬 𝐚𝐭 𝐚𝐧𝐲 𝐭𝐢𝐦𝐞 𝐟𝐫𝐨𝐦 𝐚𝐧𝐲 𝐝𝐞𝐯𝐢𝐜𝐞 𝐚𝐧𝐝 𝐚𝐧𝐲𝐰𝐡𝐞𝐫𝐞. 𝐅𝐨𝐫 𝐦𝐨𝐫𝐞 𝐝𝐞𝐭𝐚𝐢𝐥𝐬, 𝐟𝐨𝐥𝐥𝐨𝐰 𝐭𝐡𝐞 𝐥𝐢𝐧𝐤: https://www.alliedmarketresearch.com/library-access
𝐀𝐛𝐨𝐮𝐭 𝐀𝐥𝐥𝐢𝐞𝐝 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of the domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
5933 NE Win Sivers Drive
205, Portland, OR 97220
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060